SEQENS
Robert Monti is an experienced executive in the consumer health care and specialty chemicals sectors. Currently serving as VP Consumer Health Care BU at SEQENS since August 2015, Robert Monti is responsible for meeting financial targets and ensuring operational compliance. Prior to SEQENS, Robert Monti held the position of Business Director NOVACYL at NOVACAP, where €130M in sales was generated through effective management of global sales and marketing teams. Robert Monti's career began at Rhodia, where significant roles included Fire Resistance Market Director, Marketing Manager in Engineering Plastics, and Global Key Accounts Manager, contributing to various strategic initiatives and innovations in fire resistance and engineering plastics markets. Robert Monti earned an engineering degree in plastics from ITECH LYON from 1988 to 1991.
This person is not in any offices
SEQENS
SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1.4 MM€ and operates 24 manufacturing plants and 10 R&D centers in Europe, North America and Asia. 3,400 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers. SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.